Early Breast Cancer Part 2: Patient and Caregiver Discussions - Patient Case #2

Thank you. You have completed this activity.

Go to Patient Case #1

In this second segment of our 3-part “Case-Based Exchange” series, Joyce O’Shaughnessy, MD, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNPO, discuss 2 patient cases with early breast cancer, outlining methods for fostering active engagement and collaborative conversations with patients and caregivers about the incorporation of abemaciclib into treatment plans.

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP

Oncology Nurse Practitioner
Texas Oncology
Dallas, TX

Related Items

Early Breast Cancer Part 2: Patient and Caregiver Discussions - Patient Case #1

Case-Based Exchange: Early Breast Cancer

In this second segment of our 3-part “Case-Based Exchange” series, Joyce O’Shaughnessy, MD, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNPO, discuss 2 patient cases with early breast cancer, outlining methods for fostering active engagement and collaborative conversations with patients and caregivers about the incorporation of abemaciclib into treatment plans.

Early Breast Cancer Part 1: Identifying Patients - Patient Case #1

Case-Based Exchange: Early Breast Cancer

In the first set of videos of this series, Joyce O’Shaughnessy, MD, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNPO, explore complementary approaches to identifying patients with breast cancer who have specific characteristics associated with a high risk of recurrence. Together, these perspectives underscore the multifaceted approach needed for effective risk assessment in early-stage breast cancer.

Early Breast Cancer Part 1: Identifying Patients - Patient Case #2

Case-Based Exchange: Early Breast Cancer

In the first set of videos of this series, Joyce O’Shaughnessy, MD, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNPO, explore complementary approaches to identifying patients with breast cancer who have specific characteristics associated with a high risk of recurrence. Together, these perspectives underscore the multifaceted approach needed for effective risk assessment in early-stage breast cancer.